Eli Lilly and Company (NYSE:LLY) Shares Sold by Comprehensive Financial Consultants Institutional Inc.

Comprehensive Financial Consultants Institutional Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,133 shares of the company’s stock after selling 32 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Comprehensive Financial Consultants Institutional Inc.’s portfolio, making the stock its 23rd largest position. Comprehensive Financial Consultants Institutional Inc.’s holdings in Eli Lilly and Company were worth $3,215,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Lorne Steinberg Wealth Management Inc. raised its holdings in shares of Eli Lilly and Company by 3.9% in the first quarter. Lorne Steinberg Wealth Management Inc. now owns 431 shares of the company’s stock valued at $335,000 after buying an additional 16 shares during the last quarter. Central Pacific Bank Trust Division purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $9,194,000. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Eli Lilly and Company by 155.1% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after buying an additional 12,004 shares during the last quarter. Whittier Trust Co. raised its holdings in shares of Eli Lilly and Company by 52.2% in the first quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock valued at $58,725,000 after buying an additional 25,877 shares during the last quarter. Finally, Mutual Advisors LLC raised its holdings in Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after purchasing an additional 50,197 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $2.90 during trading hours on Wednesday, hitting $935.40. The company’s stock had a trading volume of 591,420 shares, compared to its average volume of 2,920,563. The business has a fifty day moving average of $838.34 and a 200-day moving average of $757.52. The stock has a market cap of $889.01 billion, a price-to-earnings ratio of 137.46, a P/E/G ratio of 2.00 and a beta of 0.41. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $939.98. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the business earned $1.62 earnings per share. The company’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on LLY. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Truist Financial reissued a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Morgan Stanley reissued an “overweight” rating and set a $1,023.00 price target on shares of Eli Lilly and Company in a report on Friday, July 5th. Bank of America reissued a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, July 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $816.78.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the sale, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at $20,835,194.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,004,704 shares of company stock worth $869,479,116. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.